Growth Metrics

Trinity Biotech (TRIB) Non-Current Debt (2016 - 2025)

Trinity Biotech's Non-Current Debt history spans 15 years, with the latest figure at $83.6 million for Q2 2025.

  • On a quarterly basis, Non-Current Debt rose 27.1% to $83.6 million in Q2 2025 year-over-year; TTM through Jun 2025 was $83.6 million, a 27.1% increase, with the full-year FY2024 number at $72.4 million, up 80.49% from a year prior.
  • Non-Current Debt hit $83.6 million in Q2 2025 for Trinity Biotech, up from $72.4 million in the prior quarter.
  • Over the last five years, Non-Current Debt for TRIB hit a ceiling of $83.6 million in Q2 2025 and a floor of $31000.0 in Q4 2021.
  • Historically, Non-Current Debt has averaged $51.8 million across 5 years, with a median of $46.8 million in 2022.
  • Biggest five-year swings in Non-Current Debt: surged 142806.45% in 2022 and later plummeted 35.47% in 2023.
  • Tracing TRIB's Non-Current Debt over 5 years: stood at $31000.0 in 2021, then surged by 142806.45% to $44.3 million in 2022, then fell by 9.46% to $40.1 million in 2023, then surged by 80.49% to $72.4 million in 2024, then grew by 15.54% to $83.6 million in 2025.
  • Business Quant data shows Non-Current Debt for TRIB at $83.6 million in Q2 2025, $72.4 million in Q4 2024, and $66.4 million in Q3 2024.